EWING, N.J., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (OTCBB: CLPM ), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that its common stock has been approved for listing on the NASDAQ Capital Market and is expected to begin trading on Monday, November 11, 2013 under the symbol CPXX. The company's common stock will continue to trade on the Over the Counter Bulletin Board, under the symbol CLPM, until the market close on Friday, November 8, 2013.
"This is an important milestone to Celator's success as a public company," said Scott Jackson, chief executive officer of Celator Pharmaceuticals. "We believe that listing with NASDAQ will raise awareness of the company with the investment community and help increase our liquidity."
About Celator Pharmaceuticals, Inc.
Celator Pharmaceuticals, Inc., with locations in Ewing, N.J., and Vancouver, B.C., is a pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®, the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes two clinical stage products, CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia and CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; and preclinical stage product candidates, including CPX-571 (a liposomal formulation of irinotecan:floxuridine), and hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation being studied by the National Cancer Institute's Nanotechnology Characterization Laboratory. For more information, please visit the company's website at www.celatorpharma.com . Information on ongoing trials is available at www.clinicaltrials.gov .
Forward-Looking Statements :
To the extent that statements contained in this press release are not descriptions of historical facts regarding Celator, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will" "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, our expectations regarding our development plans for and the potential efficacy, therapeutic potential of our drug candidates, our expectations regarding the trading of our common stock and other matters that could affect the availability or commercial potential of our drug candidates. Celator undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Celator's Form 10-K for the year ended December 31, 2012 and other filings by the company with the U.S. Securities and Exchange Commission.
Media: Mike Beyer, Sam Brown, Inc. 773-463-4211, Investors: Beth DelGiacco, Stern Investor Relations, Inc. (212) 362-1200,
